Richa Sharma/X
Sep 3, 2025, 12:48
Richa Sharma Shares ARCADIA Post-Hoc Findings: Apixaban Prevents Recurrent Stroke in ESUS Patients with LV Dysfunction
Richa Sharma, Associate Professor of Neurology at Yale School of Medicine, has shared a post on X:
“Lower risk of recurrent stroke among patients with ESUS and left ventricular dysfunction randomized to apixaban in the ARCADIA trial in our post-hoc analysis.”
Title: Lower risk of recurrent stroke among patients with ESUS and left ventricular dysfunction randomized to apixaban in the ARCADIA trial in our post-hoc analysis.
Authors: Richa Sharma, Dinesh Jillella, Cenai Zhang, Mitchell S.V. Elkind, Hooman Kamel, Marco R. Di Tullio, Richard A. Kronmal, Balaji Krishnaiah, Shadi Yaghi, W.T. Longstreth Jr, David Tirschwell, Alexander Merkler, Fadi Nahab
Read the full article here.
Find similar posts on Hemostasis Today.
-
May 24, 2026, 17:48Flora Peyvandi: Crucial Role of Placental ADAMTS13 in Perinatal Survival
-
May 24, 2026, 17:13Mahtab Mashayekhi: The Evolving Role of Red Blood Cell Exchange in the Management of SCD
-
May 24, 2026, 17:12Silvina Graña: Helping Families Better Understand Hemophilia and Daily Life With Bleeding Disorders
-
May 24, 2026, 17:11Miikka Vikkula: Key Insights from the ISSVA 2026 World Congress
-
May 24, 2026, 17:10Mathieu Jackson: Proud to Be Present at This Historic Moment for the Global Bleeding Disorders Community
-
May 24, 2026, 17:09Ramina Fazeli: Highlighting the Emerging Role of Neutrophil Extracellular Traps in Ovarian Cancer
-
May 24, 2026, 16:12William Wallace: Normal B12 Levels May Still Cause Brain Damage and Cognitive Decline
-
May 24, 2026, 15:54Marc Carrier: Ottawa Race Weekend Raised Over 7,000 USD for Thrombosis Canada
-
May 24, 2026, 15:44Janak Sadhu: Building a Stroke-Free Mehsana Through Community Awareness and Healthcare Collaboration